ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells
American Journal of Physiology-Cell Physiology · 2024
DOI: 10.1152/ajpcell.00188.2024 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Cell Physiology, 2024. Verfasst von Veronika Nemethova und 13 weiteren Autor:innen. Beteiligte Einrichtung: Selecta Biotech SE, Bratislava, Slovakia. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Fusion Proteins, bcr-abl. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Agentúra na Podporu Výskumu a Vývoja (APVV), Vedecká Grantová Agentúra MŠVVaŠ SR a SAV (VEGA), Ministerstvo Zdravotnictví Ceské Republiky (MZCR).
Abstract (Originalsprache)
Effective treatment modalities targeting leukemic clones that escape tyrosine kinase inhibitor (TKI) therapy could be game changers in the professional management of patients displaying primary resistance, intolerance, or acquired resistance to TKIs. Although delivering authentic innovations today is more complex than ever, we developed a highly potent and safe oligonucleotide-based modality against BCR-ABL1 mRNA named ASP210 that effectively induces cell death in BCR-ABL1-positive TKI-resistant cells while sparing BCR-ABL1-negative healthy cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Selecta Biotech SE, Bratislava, Slovakia.
- Department of Hematology and Transfusiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
- Department of Nanobiology, Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.
- Centre for Advanced Materials Application, Slovak Academy of Sciences, Bratislava, Slovakia.
- Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic.
ORCID-Profile: Veronika Nemethova, Andrea Babelova
Förderung
- Agentúra na Podporu Výskumu a Vývoja (APVV)
- Vedecká Grantová Agentúra MŠVVaŠ SR a SAV (VEGA)
- Ministerstvo Zdravotnictví Ceské Republiky (MZCR)
- Slovenská Akadémia Vied (SAV)
Zitieren
APA
Nemethova, V., Babiakova, P., Teglasova, B., Uhelska, L., Babelova, A., Selc, M., Jakic, K., Mitrovsky, O., Myslivcova, D., Zackova, M., Poturnayova, A., Batorova, A., Drgona, L., & Razga, F. (2024). ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.00188.2024
Vancouver
Nemethova V, Babiakova P, Teglasova B, Uhelska L, Babelova A, Selc M, et al. ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells. American Journal of Physiology-Cell Physiology. 2024. doi:10.1152/ajpcell.00188.2024
BibTeX
@article{Nemethova2024,
author = {Nemethova, Veronika and Babiakova, Petra and Teglasova, Boglarka and Uhelska, Lucia and Babelova, Andrea and Selc, Michal and Jakic, Kristina and Mitrovsky, Ondrej and Myslivcova, Denisa and Zackova, Marketa and Poturnayova, Alexandra and Batorova, Angelika and Drgona, Lubos and Razga, Filip},
title = {ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells},
journal = {American Journal of Physiology-Cell Physiology},
year = {2024},
doi = {10.1152/ajpcell.00188.2024}
}
EUVIMED